August 31, 2017 / 11:21 AM / 4 months ago

BRIEF-Daiichi Sankyo terminates product agreement with Charleston Laboratories

Aug 31 (Reuters) - Daiichi Sankyo Co Ltd

* Daiichi Sankyo terminates development and commercialization agreement with Charleston Laboratories regarding hydrocodone products in the U.S., including CL-108

* Daiichi Sankyo Co Ltd - ‍will take impaired loss of about 27.8 billion yen (250 million U.S. dollars) in 2nd quarter consolidated financial result for FY2017​

* Daiichi Sankyo Co Ltd - ‍impaired loss reflects payments made to Charleston Laboratories under terms of agreement​

* Daiichi Sankyo- co, U.S. unit has elected to terminate its 2014 development and commercialization agreement with Charleston Laboratories​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below